Controlled transdermal iontophoresis for poly-pharmacotherapy: Simultaneous delivery of granisetron, metoclopramide and dexamethasone sodium phosphate in vitro and in vivo.

Iontophoresis has been used to deliver small molecules, peptides and proteins into and across the skin. In principle, it provides a controlled, non-invasive method for poly-pharmacotherapy since it is possible to formulate and to deliver multiple therapeutic agents simultaneously from the anodal and cathodal compartments. The objective of this proof-of-principle study was to investigate the simultaneous anodal iontophoretic delivery of granisetron (GST) and metoclopramide (MCL) and cathodal iontophoresis of dexamethasone sodium phosphate (DEX-P). In addition to validating the hypothesis, these are medications that are routinely used in combination to treat chemotherapy-induced emesis. Two preliminary in vitro studies using porcine skin were performed: Study 1 - effect of formulation composition on anodal co-iontophoresis of GST and MCL and Study 2 - combined anodal iontophoresis of GST (10mM) and MCL (110 mM) and cathodal iontophoresis of DEX-P (40 mM). The results from Study 1 demonstrated the dependence of GST/MCL transport on the respective drug concentrations when co-iontophoresed at 0.3 mA·cm(-2). Although they possess similar physicochemical properties, MCL seemed to be a more efficient charge carrier (JMCL=0.0591∗CMCLvs JGST=0.0414∗CGST). In Study 2, MCL permeation was markedly superior to that of GST (2324.83 ± 307.85 and 209.83 ± 24.84 μg·cm(-2), respectively); this was consistent with the difference in their relative concentrations; DEX-P permeation was 336.94 ± 71.91 μg·cm(-2). The in vivo studies in Wistar rats (10mM GST, 110 mM MCL and 40 mM DEX-P (0.5 mA·cm(-2) for 5h with Ag/AgCl electrodes and salt bridges) demonstrated that significant drug levels were achieved rapidly for each drug. This was most noticeable for dexamethasone (DEX) where relatively constant plasma levels were obtained from the 1 to 5h time-points; DEX-P was not detected in the plasma since it was completely hydrolyzed to the active metabolite. The calculated input rates in vivo (k01) for GST, MCL and DEX were 0.45 ± 0.05, 3.29 ± 0.48 and 1.97 ± 0.38 μg·cm(-2) · min(-1), respectively. The study confirmed that iontophoresis provided a controlled method for the simultaneous administration of multiple therapeutic agents and that it could be of use for poly-pharmacotherapy in general and more specifically that it was able to deliver different drugs used in the treatment of chemotherapy-induced emesis.

[1]  R. G. Welsh,et al.  Iontophoretic drug delivery system. , 1996, Seminars in interventional cardiology : SIIC.

[2]  A. Chaturvedula,et al.  Dermal, Subdermal, and Systemic Concentrations of Granisetron by Iontophoretic Delivery , 2005, Pharmaceutical Research.

[3]  Yannic B Schuetz,et al.  Transdermal iontophoretic delivery of triptorelin in vitro. , 2005, Journal of pharmaceutical sciences.

[4]  M. Maltoni,et al.  A double-blind randomized study comparing intramuscular (i.m.) granisetron with i.m. granisetron plus dexamethasone in the prevention of delayed emesis induced by cisplatin , 1999 .

[5]  M. Kris,et al.  American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J E Riviere,et al.  Interspecies and interregional analysis of the comparative histologic thickness and laser Doppler blood flow measurements at five cutaneous sites in nine species. , 1990, The Journal of investigative dermatology.

[7]  Y. Kalia,et al.  Transdermal Delivery of Cytochrome C—A 12.4 kDa Protein—Across Intact Skin by Constant–Current Iontophoresis , 2007, Pharmaceutical Research.

[8]  G. de Pouvourville,et al.  Incidence of chemotherapy‐induced nausea and emesis after modern antiemetics , 2004, Cancer.

[9]  S. Dubey,et al.  Non-invasive iontophoretic delivery of enzymatically active ribonuclease A (13.6 kDa) across intact porcine and human skins. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[10]  Y. Tam,et al.  Dose-dependent pharmacokinetics of metoclopramide in rat: an effect of hemoperfusion? , 1981, The Journal of pharmacology and experimental therapeutics.

[11]  Y. Kalia,et al.  Structure-permeation relationships for the non-invasive transdermal delivery of cationic peptides by iontophoresis. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[12]  S. Jacobsen,et al.  Iontophoresis of dexamethasone: laboratory studies , 1992 .

[13]  I. T. G. Roup Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. , 2000, The New England journal of medicine.

[14]  P. Santi,et al.  The Influence of Iontophoresis on Acyclovir Transport and Accumulation in Rabbit Ear Skin , 2005, Pharmaceutical Research.

[15]  S. Dubey,et al.  Understanding the poor iontophoretic transport of lysozyme across the skin: when high charge and high electrophoretic mobility are not enough. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[16]  W. Jusko,et al.  Comparison of dexamethasone pharmacokinetics in female rats after intravenous and intramuscular administration , 2005, Biopharmaceutics & drug disposition.

[17]  W. Leppert,et al.  Treatment of nausea and vomiting in advanced cancer , 2003 .

[18]  M. Cormier,et al.  Effect of transdermal iontophoresis codelivery of hydrocortisone on metoclopramide pharmacokinetics and skin-induced reactions in human subjects. , 1999, Journal of pharmaceutical sciences.

[19]  C. Spencer,et al.  Tropisetron , 2000, Drugs.

[20]  C. Kitagawa,et al.  Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. , 2009, The Lancet. Oncology.

[21]  L. Scapozza,et al.  Noninvasive transdermal iontophoretic delivery of biologically active human basic fibroblast growth factor. , 2011, Molecular pharmaceutics.

[22]  Ning Li,et al.  Basic Statistics and Pharmaceutical Statistical Applications , 2000 .

[23]  T. Gan,et al.  Meta-Analysis of the Safety of 5-HT3 Antagonists with Dexamethasone or Droperidol for Prevention of PONV , 2006, The Annals of pharmacotherapy.

[24]  M. Danhof,et al.  Iontophoretic delivery of apomorphine. II: An in vivo study in patients with Parkinson's disease. , 1997, Pharmaceutical research.

[25]  S. Kežić,et al.  Evaluation of in-vivo animal and in-vitro models for prediction of dermal absorption in man , 2008, Human & experimental toxicology.

[26]  P. Hesketh Clinical Science Review: Comparative Review of 5-HT3 Receptor Antagonists in the Treatment of Acute Chemotherapy-Induced Nausea and Vomiting , 2000, Cancer investigation.

[27]  R Panchagnula,et al.  Animal models for transdermal drug delivery. , 1997, Methods and findings in experimental and clinical pharmacology.

[28]  H. Möllmann,et al.  HPLC determination of glucocorticoid alcohols, their phosphates and hydrocortisone in aqueous solutions and biological fluids. , 1986, Journal of Pharmaceutical and Biomedical Analysis.

[29]  Y. Kalia,et al.  Using transdermal iontophoresis to increase granisetron delivery across skin in vitro and in vivo: effect of experimental conditions and a comparison with other enhancement strategies. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[30]  A. Plenis,et al.  Sensitive quantification of chosen drugs by reversed-phase chromatography with electrochemical detection at a glassy carbon electrode. , 2006, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[31]  J. Atkins,et al.  Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5‐hydroxytryptamine‐3 antiemetics , 2003, Cancer.

[32]  Y. Kalia,et al.  Transdermal Iontophoretic Delivery of Vapreotide Acetate AcrossPorcine Skin in Vitro , 2005, Pharmaceutical Research.

[33]  Y. Kalia,et al.  Mathematical models to describe iontophoretic transport in vitro and in vivo and the effect of current application on the skin barrier. , 2013, Advanced drug delivery reviews.

[34]  Y. Kalia,et al.  Transdermal iontophoresis of dexamethasone sodium phosphate in vitro and in vivo: effect of experimental parameters and skin type on drug stability and transport kinetics. , 2010, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[35]  A. Dakkuri,et al.  Nasal absorption of ondansetron in rats: an alternative route of drug delivery , 2000, Cancer Chemotherapy and Pharmacology.

[36]  Sean C. Sweetman,et al.  Martindale: The Complete Drug Reference , 1999 .

[37]  J. Gyory,et al.  Transdermal ion migration , 1992 .

[38]  Y. Kalia,et al.  Comparing metoclopramide electrotransport kinetics in vitro and in vivo. , 2010, European Journal of Pharmaceutical Sciences.